Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Cell Free MYC DNA Copy Number Identifies High-Risk Smouldering Myeloma and Newly Diagnosed Multiple Myeloma

Daniel Wong, John Reynold, Cameron Wellard, Nicholas Bingham, Jessie Zhao, Malarmathy Ramachandran, Hang Quach, Simon Gibbs, Tiffany T. Khong, Sridurga Mithraprabhu, Andrew Spencer

Blood (2023) 142 (Supplement 1): 878.

https://doi.org/10.1182/blood-2023-185329

Published: 2023

Journal Articles

Multiple Myeloma-Derived Circulating Extracellular Vesicles Affect Normal Human Stromal Cell Behaviour and Promote Tumor Progression: A Multi-Omic Approach

Antonia Reale, Irena Carmichael, Rong Xu, Haoyun Fang, Jaynish S Shah, Tiffany Khong, Nicholas Bingham, Malarmathy Ramachandran, Maoshan Chen, David W Greening, Andrew Spencer

Blood (2022) 140 (Supplement 1): 7080–7081.

https://doi.org/10.1182/blood-2022-168440

Published: 2022

Journal Articles

Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial)

Anna Kalff, MBBS (Hons) FRACP FRCPA, Sam Norton, PhD, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Mary H. Young, PhD, William Pierceall, Anjan Thakurta, Udo Oppermann, PhD, Manman Guo, John Reynolds, PhD, Andrew Spencer

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141746

Published: 2020

Journal Articles

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

Anna Kalff, MBBS, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Sam Norton, PhD, Andrew Mitchell, PhD, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Nola Kennedy, Roslyn Kemp, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3186.

https://doi.org/10.1182/blood-2019-130154

Published: 2019

Journal Articles

Identification of Acetylation, Immune Cell Alterations and Gene Signature As Dynamic Biomarkers of Response to Panobinostat Treatment in Multiple Myeloma Patients

Sridurga Mithraprabhu, PhD MSc, Ioanna Savvidou, MD, Malarmathy Ramachandran, Anna Kalff, MBBS, Tiffany T. Khong, BSc,PhD, Kate Reed, John Reynolds, PhD, Andrew Spencer, MD

Blood (2017) 130 (Supplement 1): 1823.

https://doi.org/10.1182/blood.V130.Suppl_1.1823.1823

Published: 2017

Journal Articles

Mutational Characterisation and Tracking Disease Progression Using Circulating Cell-Free Tumor DNA in Multiple Myeloma Patients

Sridurga Mithraprabhu, PhD, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Annie W.S. Chow, Daniela Klarica, RN, Laura Mai, Stephanie Walsh, David Broemeling, Andre Marziali, Matthew Wiggin, Jay Hocking, MD PhDstudent, Anna Kalff, MBBS, FRACP, FRCPA, Brian G.M. Durie, MD, Andrew Spencer

Blood (2016) 128 (22): 3280.

https://doi.org/10.1182/blood.V128.22.3280.3280

Published: 2016

Journal Articles

TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma

Antonia Reale, MD Oncologist in training, Tiffany Khong, BSc, PhD, Sridurga Mithraprabhu, PhD, John Reynolds, Malarmathy Ramachandran, Ioanna Savvidou, MD PhD, Krystal Bergin, Jay Hocking, MD PhDstudent, Andrew Spencer

Blood (2016) 128 (22): 4461.

https://doi.org/10.1182/blood.V128.22.4461.4461

Published: 2016

Journal Articles

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Anna Kalff, MBBS, FRACP, FRCPA, Sridurga Mithraprabhu, PhD, Tiffany T. Khong, PhD, Malarmathy Ramachandran, Kate Reed, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Krystal Bergin, Andrew Spencer

Blood (2016) 128 (22): 4515.

https://doi.org/10.1182/blood.V128.22.4515.4515

Published: 2016

Journal Articles

Roar: A Phase Ib Trial of Oral Azacitidine (CC-486) in Combination with Lenalidomide and Dexamethasone (Rd) for Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma Who Have Failed a Prior Lenalidomide-Containing Regimen

Anna Kalff, MBBS, FRACP, FRCPA, Kate Reed, Tiffany T. Khong, PhD, Sridurga Mithraprabhu, PhD, Malarmathy Ramachandran, John Reynolds, Krystal Bergin, Anjan Thakurta, PhD, Maria Wang, PhD, Andrew Spencer, Roberto Guzman, Suzana Cuoto, Yan Ren, MD

Blood (2016) 128 (22): 2121.

https://doi.org/10.1182/blood.V128.22.2121.2121

Published: 2016

Journal Articles

Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide

Anna Kalff, MD, Kate Reed, Tiffany T. Khong, PhD, Sridurga Mithraprabhu, Post doc, Malarmathy Ramachandran, Richard Hall, Krystal Bergin, MBBS, Andrew Spencer

Blood (2015) 126 (23): 3033.

https://doi.org/10.1182/blood.V126.23.3033.3033

Published: 2015

Journal Articles

TOP2A Knockdown Resensitizes Carfilzomib-Resistant Hmcls to Carfilzomib

Antonia Reale, Oncologist in training, Tiffany T. Khong, BSc, PhD, Sridurga Mithraprabhu, Post doc, Ioanna Savvidou, MD PhDstudent, Malarmathy Ramachandran, Andrew Spencer

Blood (2015) 126 (23): 4215.

https://doi.org/10.1182/blood.V126.23.4215.4215

Published: 2015

Journal Articles

Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma

Andrew Spencer, Sridurga Mithraprabhu, Post doc, Malarmathy Ramachandran, Daniela Klarica, RN, Jay Hocking, MD, Laura Mai, Stephanie Walsh, David Broemeling, Andre Marziali, Anna Kalff, MD, Matthew Wiggin, Brian G. M. Durie, MD, Tiffany T. Khong, PhD

Blood (2015) 126 (23): 368.

https://doi.org/10.1182/blood.V126.23.368.368

Published: 2015

NARROW

Cell Free MYC DNA Copy Number Identifies High-Risk Smouldering Myeloma and Newly Diagnosed Multiple Myeloma

Multiple Myeloma-Derived Circulating Extracellular Vesicles Affect Normal Human Stromal Cell Behaviour and Promote Tumor Progression: A Multi-Omic Approach

Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial)

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

Identification of Acetylation, Immune Cell Alterations and Gene Signature As Dynamic Biomarkers of Response to Panobinostat Treatment in Multiple Myeloma Patients

Mutational Characterisation and Tracking Disease Progression Using Circulating Cell-Free Tumor DNA in Multiple Myeloma Patients

TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Roar: A Phase Ib Trial of Oral Azacitidine (CC-486) in Combination with Lenalidomide and Dexamethasone (Rd) for Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma Who Have Failed a Prior Lenalidomide-Containing Regimen

Roar: A Phase Ib Trial of Oral Azacitidine in Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma (MM) Patients Refractory to Prior Lenalidomide

TOP2A Knockdown Resensitizes Carfilzomib-Resistant Hmcls to Carfilzomib

Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only